Аrginase/NO-synthase system сharacteristics in blood lymphocytes under effect of fluoroquinolones

  • І. V. Кovalenko Danylo Halytsky Lviv National Medical University
  • О. K. Оnufrovych Danylo Halytsky Lviv National Medical University
  • N. M. Vorobets Danylo Halytsky Lviv National Medical University
  • О. V. Меlnyk Danylo Halytsky Lviv National Medical University
  • Z. D. Vorobets Danylo Halytsky Lviv National Medical University
Keywords: fluoroquinolones; moxifloxacin; levofloxacin; ciprofloxacin; lymphocytes; arginase; NO-synthase.


Antibiotics of the fluoroquinolone series are highly effective synthetic drugs of a wide range of antimicrobial activity. They have a specific mechanism of action on bacterial cells to inhibit the DNA-gyrase enzyme of mostly gram-negative and the topoisomerase IV of gram-positive bacterial cells, which leads to a decrease in the activity of enzymes, disruption of DNA and RNA biosyntheses, and the impossibility of chromosome superspilarization, as a result of which its division is broken and the cell dies. Fluoroquinolones also have an immunomodulatory effect, which is very important in terms of the pathogenesis of many infectious and inflammatory diseases. We assume that fluoroquinolones also act on cells of the body of patients, in particular on such regulatory mechanisms as the arginase-NO-synthase system. In this regard, peripheral blood lymphocytes can be a convenient and adequate model for studying the mechanism of the effect of fluoroquinolones. It is shown that under the influence of various generations of fluoroquinolones, arginase activity increases, depending on the dose, in the following sequence: control → ciprofloxacin → levofloxacin → moxifloxacin. The highest activity is observed under the effects of moxifloxacin, belonging to generation IV. The increase in arginase activity in blood lymphocytes under the influence of fluoroquinolones occurs due to the growth of turnover number of the enzymes (Vmax increases), although the affinity of enzyme to the substrate decreases (KL-arg increases). At the same time, all fluoroquinolones reduce the activity of the constitutive isoforms of NO-synthase, depending on the dose. It has been established that a slight activity of iNOS of blood lymphocytes in practically healthy women was detected, almost on the verge of error. When studying the influence of fluoroquinolones on the activation of iNOS lymphocytes isolated from the blood of practically healthy women, we did not observe its activity, and the inhibitive effect could not be determined due to its low activity. Oxidative stress was used to induce iNOS activity in blood lymphocytes, with H2O2 lymphocytes preincubation. The preincubation of lymphocytes with 0.2 mM H2O2 leads to increase of iNOS activity by 31.30 times. By activation of iNOS with hydrogen peroxide, 10–5 M concentration of ciprofloxin leads to inhibition of enzyme activity by 1.22 times, levofloxacin by 1.45 and moxifloxacin by 2.34 times. The obtained kinetic parameters suggest that in the blood lymphocytes under the influence of fluoroquinolones, the synthesis of NO with the participation of cNOS is inhibited, and the hyperproduction of NO is inhibited by the activation of iNOS, which is characteristic for pathological conditions.


Almakaeva, L. G., Begunova, N. V., Naumenok, L. G., Dolya, V. G., & Almakaev, М. S. (2015). Rozrobka skladu infuziynoho preparatu na osnovi moksyfloksatsynu [Development of composition of infusion medication on basis of moxifloxacin]. Anali Mečnikìvskogo Institutu, 2, 70–73 (in Ukrainian).

Ambulkar, P. S., Ghosh, S. K., Indole, I. V., & Pal, A. K. (2009). Genotoxic and cytotoxic effects of antibacterial drug, ciprofloxacin, on human lymphocytes in vitro. Nepal Medical College Journal, 11(3), 147–151.

Bogdan, C. (2011). Regulation of lymphocytes by nitric oxide. Methods in Molecular Biology, 677, 375–393.

Boyum, A. (1968). Isolation of mononuclear cells and granulocytes from human blood. Scandinavian Journal of Clinical and Laboratory Investigation, 21(97), 77–89.

Bryan, N. S., Bian, K., & Murad, F. (2009). Discovery of the nitric oxide signaling pathway and targets for drug development. Frontiers in Bioscience, 14, 1–18.

Chatzika, K., Manika, K., Kontou, P., Pitsiou, G., Papakosta, D., Zarogoulidis, K., & Kioumis, I. (2014). Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. Antimicrobial Agents and Chemotherapy, 58(3), 1315–1319.

Chen, T.-C., & Chang, S.-W. (2017). Moxifloxacin modulated TGF-β1-related interleukin-12 secretion in corneal fibroblasts. Investigative Ophthalmology & Visual Science, 58, 5692–5702.

Combet, S., Balligand, J. L., Lameire, N., Goffin, E., & Devuyst, O. (2000). A specific method for measurement of nitric oxide synthase enzymatic activity in peritoneal biopsies. Kidney International, 57(1), 332–338.

Demchuk, H. V. (2014). Otsinka bezpechnosti ftorkhinoloniv pry likuvanni neuspitalnoyi pnevmoniyi v osobakh z tsukrovym diabetom [Estimation of safety of fluoroquinolones for therapy of community-acquired pneumonia of the patients with diabetes mellitus]. Visnyk Vinnytskoho Mededychnogo Universitetu, 18(2), 525–528 (in Ukrainian).

Demir, S., Ural, D., & Olgac, M. (2018). An anusual dual hypersensitivity reaction to moxifloxacin in a patients. Asian Pacific Journal of Allergy, 8(3), 26–31.

Dudikova, M. L., Vrynchanu, N. O., & Dronova, M. L. (2015). Novi antybiotyky khinolonovoho ryadu: Perspektyvy zastosuvannya v klinichniy praktytsi [New antibiotics of the quinolone series: Prospects for use in medical practice]. Pharmacologia i Likarska Toxicologia, 432, 3–12 (in Ukrainian).

Fafula, R. V., Iefremova, U. P., Luchkovska, N. E., Vorobets, Z. D., & Kulachkovskii, O. R. (2012). Metodolohichnyy pidkhid do vyvchennya enzymetychnoho spektru limfotsytiv pry patolohichnykh stanakh z vykorystannyam deterhentu saponinu (ultrastrukturnoho doslidzhennya) [Methodological approach to the study of the enzymatic spectrum of lymphocytes at pathological states using a detergent of saponin (ultrastructural study)]. Visnyk Problem Biolohiyi ta Medytsyny, 96, 163–166 (in Ukrainian).

Forstermann, U., & Sessa, W. (2012). Nitric oxide synthase: Regulation and function. European Heart Journal, 33(7), 829–837.

Kanyuka, O., & Pauliv, O. (2011). Perspektyvy zastosuvannya ftorkhinoloniv IV pokolinnya v likuvanni bakterialnykh infektsiy [Future use flioroquinolone IV generation in treatment bacterial infections]. Naukovyi Visnyk S. Gzhytskoho LNUVMBT, 48, 107–111 (in Ukrainian).

Kolios, G., Manousou, P., Bourikas, L., Notas, G., Tsagarakis, N., Mouzas, I., & Kouroumalis, E. (2006). Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. The European Journal of Clinical Investigation, 36(10), 720–729.

Komisarenko, S. V. (2002). Molekulyarni mekhanizmy aktyvatsiyi limfotsytiv [Molecular mechanisms of activation of lymphocytes]. The Ukrainian Biochemical Journal, 74(4), 8 (in Ukrainian).

Majhi, A., Adhikary, R., Bhattacharyya, A., & Mahanti, S. (2014). Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin. Antimicrobial Agents and Chemotherapy, 58(9), 5164–5180.

Mielczarek-Puta, M., Chrzanowska, A., & Bara, E. (2008). New insights into arginase. Part I. Structure and characteristics. Advances in Hygiene and Experimental Medicine, 62, 206–213.

Mielczarek-Puta, M., Chrzanowska, A., & Grabo, E. (2008). New insights into arginase. Part II. Role in physiology and pathology. Advances in Hygiene and Experimental Medicine, 62, 214–221.

Paliy, G. K., Nazarchuk, O. A., Nahajchuk, V. I., Osadchuk, N. I., Paliy, D. V., & Kovalenko, I. V. (2015). Analitychne prohnozuvannya chutlyvosti stafilokoku do ftorkhinoloniv [Analytic prognostication of sensitivity of staphilococcus to fluoroquinolones]. Svit Medytsyny ta Biolohiyi, 51, 103–106 (in Ukrainian).

Potjo, M., Cockeran, R., Theron, A. J., Feldman, C., & Anderson, R. (2010). Effect of moxifloxacin on human neutrophil and T-lymphocyte functions in vitro. Pharmaceuticals, 3, 3570–3580.

Riesbeck, K. (2002). Immunomodulating activity of quinolones: Review. Journal of Chemotherapy, 14(1), 3–12.

Shugaley, V. S., & Kozina, A. S. (1977). Soderzhaniye mocheviny i aktivnost' arginazy v organakh krys pri akklimatizatsii k kholodu [Urea content and arginase activity in rat organs when acclimated to cold]. Fiziologicheskiy Zhurnal, 8, 1199–1202 (in Russian).

Thomas, S., Kotamraju, S., Zielonka, J., Harder, D. R., & Kalyanaraman, B. (2007). Hydrogen peroxide induced nitricoxide and proteasome activity in endothelial cell: A bell-shaped signaling response. Free Radical Biology and Medicine, 42(7), 1049–1061.

Werber, S., Shalit, I., Fabian, I., Steuer, G., Weiss, T., & Blau, H. (2005). Moxifloxacin inhibits cytokine MAP kinase and NF-kB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line. Journal of Antimicrobial Chemotherapy, 55, 293–300.

How to Cite
КovalenkoІ. V., ОnufrovychО. K., Vorobets, N. M., МеlnykО. V., & Vorobets, Z. D. (2019). Аrginase/NO-synthase system сharacteristics in blood lymphocytes under effect of fluoroquinolones . Regulatory Mechanisms in Biosystems, 10(2), 203-208. https://doi.org/10.15421/021930

Most read articles by the same author(s)